Outlook Therapeutics Inc
F:41O
Outlook Therapeutics Inc
F:41O
Price:
0.53
EUR
-0.56%
Market Closed
Market Cap:
€23.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Outlook Therapeutics Inc
F:41O
|
US |
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3m | 3.8m | 3.1m | 8.1m | 0 | 0 | 0 | 0 | 0 | 1.4m | |
| — | — | — | — | — | — | — | — | — | (1.4m) | |
| — | — | — | — | — | — | — | — | — | 57.2k | |
| (54.3m) | (39.7m) | (32.7m) | (33.2m) | (36.3m) | (51.7m) | (63.1m) | (53.1m) | (71.7m) | (67.1m) | |
| (21.6m) | (15.9m) | (14.2m) | (9.4m) | (10m) | (12.8m) | (20.7m) | (26.7m) | (29.9m) | (39.9m) | |
| (32.8m) | (23.8m) | (18.5m) | (23.8m) | (26.3m) | (39m) | (42.3m) | (26.5m) | (41.8m) | (27.2m) | |
| (51.3m) | (35.9m) | (29.6m) | (25m) | (36.3m) | (51.7m) | (63.1m) | (53.1m) | (71.7m) | (67.1m) | |
| (1.9m) | (5.6m) | (3.9m) | (3.5m) | (1.8m) | (982.5k) | (1.5m) | (1.6m) | (2.4m) | (334.4k) | |
| 1.9m | 5.6m | 3.9m | 3.5m | 1.8m | 936.1k | 1.5m | 2.5m | 3.2m | 283.1k | |
| — | — | (1.3m) | (11.9m) | (2.4m) | 0 | (1m) | (577.7k) | — | — | |
| 0 | 3.2m | 1m | 2.4m | 2m | (452.2k) | (417.1k) | (3.7m) | (1.3m) | 3.4m | |
| (53.2m) | (38.3m) | (33.7m) | (37.9m) | (38.5m) | (53.2m) | (66m) | (59m) | (75.4m) | (64m) | |
| (103k) | (501.5k) | 3.6m | 3.4m | 3.3m | (2k) | (2.8k) | (2.8k) | (2.8k) | 1.6m | |
| (53.3m) | (38.8m) | (30.1m) | (34.5m) | (35.2m) | (53.2m) | (66.1m) | (59m) | (75.4m) | (62.4m) | |
| (63.1m) | (40m) | (48m) | (36m) | (48.9m) | (53.2m) | (66.1m) | (59m) | (75.4m) | (62.4m) | |
| (586.79) | (266.66) | (194.72) | (39.62) | (13.47) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
A cash-generative biotech transitioning from legacy MS to acquired growth platforms
A rapidly scaled RNAi platform moving from R&D losses to product profitability
A global oncology platform moving from costly R&D expansion toward scalable profitability
A pre-commercial oncology platform funded by escalating losses and repeated capital raises
Continue 41O Research
Other Outlook Therapeutics Inc listings:
